Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Completed
Novartis Pharmaceuticals
Phase 2
2003-06-01
Primary Objective:
1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation,
Imatinib and Docetaxel (HID) in high-risk localized prostate cancer.
Secondary Objectives:
1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant
HID and radical prostatectomy in high-risk localized prostate cancer.
2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor
Receptor (PDGFR) pathway.
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Completed
M.D. Anderson Cancer Center
Phase 2
2003-06-01
Primary Objective:
1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation,
Imatinib and Docetaxel (HID) in high-risk localized prostate cancer.
Secondary Objectives:
1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant
HID and radical prostatectomy in high-risk localized prostate cancer.
2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor
Receptor (PDGFR) pathway.
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
Completed
QPS-Qualitix
Phase 3
2014-08-01
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of
subjects with advanced prostate carcinoma, when administered as two injections six months
apart.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
